



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Kristine Erickson
✉ kerickson@tourmalinebio.com

RECEIVED 04 June 2025

ACCEPTED 10 June 2025

PUBLISHED 16 July 2025

CITATION

Murdock J, Nguyen J, Hurtgen BJ, Andorfer C, Walsh J, Lin A, Tubbs C, Erickson K and Cockerham K (2025) Correction: The role of IL-6 in thyroid eye disease: an update on emerging treatments. *Front. Ophthalmol.* 5:1641164. doi: 10.3389/fopht.2025.1641164

COPYRIGHT

© 2025 Murdock, Nguyen, Hurtgen, Andorfer, Walsh, Lin, Tubbs, Erickson and Cockerham. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: The role of IL-6 in thyroid eye disease: an update on emerging treatments

Jennifer Murdock¹, John Nguyen², Brady J. Hurtgen³, Cathy Andorfer³, John Walsh³, Andrea Lin³, Christopher Tubbs³, Kristine Erickson^{3*} and Kimberly Cockerham⁴

¹Jennifer Murdock MD, PLLC, Miami, FL, United States, ²School of Medicine, West Virginia University, Morgantown, WV, United States, ³Tourmaline Bio, Inc., New York, NY, United States, ⁴Department of Surgery, Sharp Grossmont Hospital for Neuroscience, La Mesa, CA, United States

KEYWORDS

IL-6, IL-6R, thyroid eye disease (TED), Graves' ophthalmopathy, Graves' orbitopathy, Graves' disease, thyroid-associated orbitopathy (TAO)

A Correction on

The role of IL-6 in thyroid eye disease: an update on emerging treatments

By Murdock J, Nguyen J, Hurtgen BJ, Andorfer C, Walsh J, Lin A, Tubbs C, Erickson K and Cockerham K (2025) *Front. Ophthalmol.* 5:1544436. doi: 10.3389/fopht.2025.1544436

Author Jennifer Murdock was erroneously assigned to affiliation “1Oculofacial Plastic Surgery, Miami, FL, United States, and 2Thrive Health, West Vancouver, BC, Canada” instead of “1Jennifer Murdock MD, PLLC, Miami, FL, United States”. This affiliation has now been updated for author Jennifer Murdock.

The conflict of interest statement has been corrected to: AL, BH, CA, CT, JW, and KE are employees of Tourmaline Bio, Inc. JM is a medical director for Thrive Health, which administers IV infusions of teprotumumab, was a consultant for Horizon/Amgen until September 2023, and has a CDA with Tourmaline Bio, Inc. for planning internal consulting and education. JM is also the CEO of Jennifer Murdock MD, PLLC. KC is a consultant and principal investigator for Horizon/Amgen, Viridian, Acelyrin, Genentech/Roche, Immunovant, ArgenX, and Tourmaline Bio, Inc. JN has received research funding from Tourmaline Bio, Inc.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.